The Health Effect of Diet Rich in Nordic Berries (Berry)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01414647 |
Recruitment Status :
Completed
First Posted : August 11, 2011
Last Update Posted : May 17, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metabolic Syndrome Impaired Glucose Tolerance Low-grade Inflammation Dyslipidemia | Dietary Supplement: 300 g of strawberry, raspberry and cloudberry Dietary Supplement: 400 g of bilberry Other: Control diet | Not Applicable |
Berries are traditionally an important part of the Nordic diet. About 50 different berries are grown in the northern region, and about half of them are edible. Phenolic compounds are one of the most diverse group of secondary metabolites present in edible plants, and berries are especially rich in them. Flavonoids, phenolic acids, lignans and complex phenolic polymers (polymeric tannins) are typical for berries. Phenolic compounds are reported to have a variety of beneficial biological properties. They are potent antioxidants, and exhibit various other physiological activities including anti-inflammatory, antimicrobial, antiallergic, anticarcinogenic and antihypertensive activities. Epidemiological studies indicate that diet rich in phenolic compound correlates with lower risk of cancer and cardiovascular disease.
The aim of the present study is to examine the effect of diet rich in berries on glucose and lipid metabolism and inflammatory markers and gene expression profile in peripheral blood mononuclear cells (PBMCs) in subjects with features of metabolic syndrome.
Randomized, controlled clinical intervention including 4 wk run-in period, 8 wk dietary intervention and 4 wk recovery period was conducted.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 56 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | The Effect of Diet Rich in Nordic Berries on Gut Microbiota, Glucose and Lipid Metabolism and Metabolism on Fenolic Compounds |
Study Start Date : | January 2006 |
Actual Primary Completion Date : | December 2006 |
Actual Study Completion Date : | March 2010 |
Arm | Intervention/treatment |
---|---|
Experimental: SRC
Strawberry, raspberry and cloudberry intervention for 8 weeks
|
Dietary Supplement: 300 g of strawberry, raspberry and cloudberry
100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted. |
Experimental: BB
Bilberry intervention for 8 weeks
|
Dietary Supplement: 400 g of bilberry
Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set. |
Experimental: C
Control diet with restricted berry consumption
|
Other: Control diet
Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
Other Name: Diet with restricted consumption of berries. |
- Glucose level [ Time Frame: week 8 ]Fasting glucose level oral glucose tolerance status at study week 8
- Cholesterol level [ Time Frame: week 8 ]total, HDL and LDL cholesterol level at the study week 8
- Inflammation markers [ Time Frame: week 8 ]Various inflammation markers were measured at the study week 8
- Markers of sterol metabolism [ Time Frame: week 8 ]Markers of cholesterol absorption and synthesis were measured
- gene expression in PBMCs [ Time Frame: study week 8 ]Global gene expression analyses in peripheral mononuclear cells (PBMC)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- overweight (BMI 26-39 kg/m2), and two of the following:
- elevated fasting plasma glucose in the absence of diabetes (5.6-6.9 mmol/l)
- abnormal serum lipid concentration: fasting serum triglyceride concentration >1.7 mmol/L, fasting serum HDL cholesterol <1.0 mmol/L (males) or <1.3 mmol/L (females))
- waist circumference >102 cm (males) or >88 cm (females)
- blood pressure >130/85 mmHg
Exclusion Criteria:
- chronic diseases
- use of lipid lowering medication

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01414647
Finland | |
University of Eastern Finland, Dpet of Public Health and Clinical Nutrition | |
Kuopio, Finland, FIN-70211 |
Principal Investigator: | Riitta Törrönen, Adjunct Professor | University of Eastern Finland |
Responsible Party: | Marjukka Kolehmainen, Senior scientist, University of Eastern Finland |
ClinicalTrials.gov Identifier: | NCT01414647 |
Other Study ID Numbers: |
124//2005 40361/05 ( Other Grant/Funding Number: Tekes, National Technology Agency of Finland ) |
First Posted: | August 11, 2011 Key Record Dates |
Last Update Posted: | May 17, 2018 |
Last Verified: | May 2018 |
Bilberry Vaccinium myrtillus Metabolic syndrome Glucose metabolism |
Lipid metabolism Inflammation Gene expression |
Metabolic Syndrome Dyslipidemias Glucose Intolerance Inflammation Pathologic Processes Insulin Resistance |
Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Lipid Metabolism Disorders Hyperglycemia |